PR Newswire · Press release
IRTC Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into iRhythm Technologies, Inc. (IRTC)
Original release from PR Newswire
As distributed by PR Newswire, unedited.
A revenue shortfall against Wall Street consensus, flat Zio AT sales, and the Zio MCT FDA submission has now slipped into 2027. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of investors who lost money.
NEW YORK, Nov. 6, 2026 /PRNewswire/ -- iRhythm Technologies, Inc. (NASDAQ: IRTC) shares opened down more than 17% and was falling by more than 30% by midday after the Company published its third-quarter report, in which management disclosed revenue of $221.6 million that came below street consensus, flat year-over-year growth for Zio AT sales, and that it no longer plans to submit its next-generation Zio MCT device to the FDA this year. If you bought IRTC and are holding a loss, this investigation into potential securities law violations may apply to you. IRTC shareholders who lost money are encouraged to submit their losses for a free review now. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.
The $221.6 million figure trailed the FactSet consensus estimate of $222.2 million. On the November 5 earnings call, management said Zio AT revenue was "roughly flat compared to the prior year," and was "below our expectations during the quarter."
Management further indicated the Zio MCT submission is now expected for submission in 2027. Notably, iRhythm tied both the slowdown in Zio AT sales and the decision to delay the Zio MCT letter to the FDA on the pending portfolio integration following the VitalConnect acquisition.
Bought IRTC and took a loss? Find out whether your IRTC losses may be recoverable, or call Joseph E. Levi, Esq. at (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the IRTC Investigation
Q: How much did IRTC stock drop?A: Shares fell roughly $22.30/share, or about 17.13% to open at about $107.89 per share on November 6, 2026. By midday, the stock had fallen by more than 30% and was trading below $87/share.
Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether iRhythm Technologies made materially false or misleading statements regarding the performance, expectations, and submission timelines of its Zio products.
Q: Who is eligible to participate in the IRTC investigation?A: Investors who purchased IRTC stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do IRTC investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my IRTC shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IRTC and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis. Any attorneys' fees and expenses are subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/irtc-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-irhythm-technologies-inc-irtc-302932307.html
SOURCE SueWallSt.com
